Accelerating an Oncology Drug Launch

January 10, 2015 Leah Hoffmann

A F300 pharma company was preparing to launch a new oncology drug. But its understaffed pricing and market access group was struggling to create global access plans and strategies. Expecting accelerated regulatory approvals in the US and Europe, the company’s Director of Global Pricing turned to Business Talent Group.

Our talent was a life science specialist from McKinsey with a background in project management and executive experience at two multi-billion-dollar biotech companies. He worked with the team to generate pre-launch insights, analytics, and country-level revenue forecasts. He also coordinated with vendors and stakeholders to accelerate the timing of the launch. Finally, he helped refine launch strategies for eight key markets, handing off to regional teams for execution.

 

Previous Article
Indication Prioritization
Indication Prioritization

The VP of Global Marketing at a F200 pharma company was reviewing a promising drug about to enter Phase II ...

Next Article
Oncology Market Access Support
Oncology Market Access Support

The lean market access group at a global pharma company was preparing to launch a recently acquired pipelin...

Get our free guide to working with on-demand talent.

Read Now